Can Bisphosphonates Prevent Vitamin K Antagonist Toxicity in Patients with Idiopathic Pulmonary Fibrosis?

Affiliations

Comment

Rob Janssen. Am J Respir Crit Care Med. 2017.

. 2017 Jan 15;195(2):269-270.

doi: 10.1164/rccm.201605-1074LE.

No abstract available

Comment in

Reply: Can Bisphosphonates Prevent Vitamin K Antagonist Toxicity in Patients with Idiopathic Pulmonary Fibrosis?
Raghu G, Rochwerg B. Raghu G, et al. Am J Respir Crit Care Med. 2017 Jan 15;195(2):271. doi: 10.1164/rccm.201608-1610LE. Am J Respir Crit Care Med. 2017. PMID: 28084827 No abstract available.
Reply: Is a Trial of Vitamin K Antagonists and Bisphosphonates Possible in IPF?
Margaritopoulos GA, Antoniou KM. Margaritopoulos GA, et al. Am J Respir Crit Care Med. 2017 Jan 15;195(2):271-272. doi: 10.1164/rccm.201608-1636LE. Am J Respir Crit Care Med. 2017. PMID: 28084829 No abstract available.

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schünemann HJ; American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association. Raghu G, et al. Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19. doi: 10.1164/rccm.201506-1063ST. Am J Respir Crit Care Med. 2015. PMID: 26177183
Can Warfarin Be Used in the Treatment of Pulmonary Embolism in Idiopathic Pulmonary Fibrosis?
Margaritopoulos GA, Antoniou KM. Margaritopoulos GA, et al. Am J Respir Crit Care Med. 2016 Apr 1;193(7):810-1. doi: 10.1164/rccm.201511-2267LE. Am J Respir Crit Care Med. 2016. PMID: 27035785 No abstract available.